SV40, genetic polymorphism and mesothelioma. Pathological and epidemiological evidence

Medicina del Lavoro

Volumn 96, Issue 4, 2005, Pages 347-353

  Magnani, Corrado ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Genetic polymorphism; Malignant mesothelioma; SV40

Indexed keywords

ASBESTOS; POLIOMYELITIS VACCINE; VIRUS DNA;

AFRICA; AGE DISTRIBUTION; CANCER INCIDENCE; CANCER RESEARCH; CONFERENCE PAPER; EUROPE; GENETIC POLYMORPHISM; HUMAN; MONKEY; NONHUMAN; PLEURA MESOTHELIOMA; PREVALENCE; SIMIAN VIRUS 40; UNITED STATES; VIRAL CONTAMINATION; VIRUS INFECTION; ANIMAL; GENETICS; MESOTHELIOMA; PATHOGENICITY; PLEURA TUMOR; REVIEW; VIROLOGY;

AFRICA; ANIMALS; EUROPE; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; POLIOVIRUS VACCINE, INACTIVATED; POLYMORPHISM, GENETIC; POLYOMAVIRUS INFECTIONS; PREVALENCE; SIMIAN VIRUS 40; TUMOR VIRUS INFECTIONS; UNITED STATES;

EID: 33645068481     PISSN: 00257818     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. BARBANTI-BRODANO G, SABBIONI S, MARTINI F, et al: Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology 2004; 318: 1-9
2. BASETSE HR, LECATSAS G, GERBER IJ: An investigation on the occurrence of SV40 antibodies in South Africa. S Afr Med J 2002; 92: 825-828
3. BOFFETTA P: Health effects of asbestos exposure in humans: A quantitative assessment. Med Lav 1998; 89: 471-480
4. BOFILL-MAS S, PINA S, GIRONES R: Documenting the epidemiologic pattern of polioma viruses in human population by studying their presence in urban sewage. Appl Env microbiol 2000; 66: 238-245
5. BUFFLER P, RICE J, BIRD M, BOFFETTA P (eds.): Mechanisms of carcinogenesis: contributions of molecular epidemiology. Lyon: IARC Scientific Publication No. 157, 2004
6. BUTEL JS, LEDNICKY JA: Cell and molecular biology of Simian Virus 40: Implications for human infections and disease. JNCI 1999; 91: 119-134
7. BUTEL JS, WONG C, VILCHEZ RA, et al: Detection of antibodies to poliomavirus SV40 in two central European countries. Centr Eur J Publ Health 2003; 11: 3-8
8. CARBONE M, PASS HI, RIZZO P, et al: Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994; 9: 1781-1790
9. CARROLL-PANKHURST C, ENGELS EA, STRICKLER HD, et al: Thirty-five year mortality following receipt of SV40-contaminated polio vaccine during the neonatal period. Br J Cancer 2001; 85: 1295-1297
10. CARTER JJ, MADELEINE MM, WIPF GC, et al: Lack of serologic evidence for prevalent Simian virus infection in Humans JNCI 2003; 95: 1522-1530
11. CICALA C, POMPETTI F, CARBONE M: SV40 induces mesothelioma in hamsters. Am J Pathol 1993; 142: 1524-1533
12. DANG-TAN T, MAHMUD SM, PUNTONI R, FRANCO EL: Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 2004; 23: 6535-6540
13. DE SANJOSE S, SHAH KV, DOMINGO-DOMENECH E, et al: Lack of serological evidence for an association between Simian Virus 40 and lymphoma. Int J Cancer 2003; 104: 522-524
14. ENGELS EA, KATKI HA, NIELSEN NM, et al: Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40. JNCI 2003; 95: 532-539
15. ENGELS EA, RODMAN LH, FRISCH M, et al: Childhood exposure to simian virus 40- contaminated poliovirus vaccine and risk of AIDS-associated non-Hodgkin's lymphoma. Int J cancer 2003; 106: 283-287
16. GARCEA RL, IMPERIALE MJ: Simian virus 40 infection of humans. J Virol 2003; 77: 5039-5045
17. GEISSLER E: SV40 and human brain tumours. Prog Med Virol 1990; 37: 211-222
18. HILLERDAL G: Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med 1999; 56: 505-513
19. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 14 Asbestos. Lyon: IARC, 1977
20. JAFAR S, RODRIGUEZ-BARRADAS M, GRAHAM DY, BUTEL JS: Serological evidence of SV40 infections in HIV-infected and HIV-negative adults. J Med Virol 1998; 54: 276-284
21. JASANI B, CRISTAUDO A, EMRI SA, et al: Association of SV40 with human tumours. Seminars in Cancer Biology 2001; 11: 49-61
22. KANE AB, SARACCI R, BOFFETTA P, WILBOURN JD (eds): IARC Scientific publication 140. Mechanisms of fibre carcinogenesis. Lyon, 1996
23. KLEIN G, POWERS A, CROCE C: Association of SV40 with human tumours. Oncogene 2002; 21: 1141-1149
24. KNOWLES W, PIPKIN P, ANDREWS N, et al: Population-based study of antibody to the human poliomaviruses BKV and JCV and the Simian polyomavirus SV40. J Med Virol 2003; 71: 115-123
25. LOPEZ-RIOS F, BILLEI P, RUSCH V, LADANYI M: Evidence against the role of SV40 infection in human mesothelioma and high risk of false-positive PCR results owing to the presence of SV40 sequences in common laboratory plasmids. Lancet 2004; 364: 1157-1166
26. MCDONALD JC, ARMSTRONG BG, EDWARDS CW, et al: Case-referent survey of young adults with mesothelioma: I. Lung fibre analyses. Ann Occup Hyg 2001; 45: 513-518
27. MINOR P, PIPKIN P, JARZEBECK Z, KNOWLES W: Studies of neutralising antibodies to SV40 in human sera. J Med Virol 2003; 70: 490-495
28. OLIN P, GIESECKE J: Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact on cancer incidence rates 1960-1993. Dev Biol Stand 1998; 94: 227-233
29. RODELSPERGER K, WOITOWITZ HJ, BRUCKEL B, et al: Dose-response relationship between amphibole fiber lung burden and mesothelioma. Cancer Detect Prev 1999; 23: 183-193
30. ROGERS AJ, LEIGH J, BERRY G, et al: Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma. A case control study. Cancer 1991; 67: 1912-1920
31. ROLLISON DEM, HELZLSOUER KJ, ALBERG AJ, et al: Serum antibodies to JC virus, BK virus, Simian virus 40 and the risk of adult astrocytic brain tumours. Cancer Epidemiol Biom Prev 2003; 12: 460-463
32. STRATTON K, ALMARIO D, MCCORMICK M: Immunization Safety Review, SV40 Contamination of Polio Vaccine and Cancer, Institute of Medicine of the National Academies(October 2002) http://books.nap.edu/books/0309086108/html/
33. STRICKLER HD, GOEDERT JJ, DEVESA SS, et al: Trends in US pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. JNCI 2003; 95: 38-45
34. STRICKLER HD, ROSENBERG PS, DEVESA SS, et al. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 1998; 279: 292-295
35. STRICKLER HD, ROSENBERG PS, DEVESA SS, et al: Contamination of poliovirus vaccine with SV40 and the incidence of medulloblastoma. Med Ped Oncol 1999; 32: 77-78
36. SWEET BH, HILLEMAN MR: The vacuolating virus SV40. Proc Soc Exp Biol Med 1960; 105: 420-427
37. VASTAG B: Sewage yields clues to SV40 transmission. JAMA 2002; 288: 1337-1338
38. VILCHEZ RA, KOZINETZ CA, ARRINGTON AS, et al: Simian virus 40 in human cancers. Am J Med 2003; 114: 675-684
39. YAMAMOTO H, NAKAYAMA T, MURAKAMI H, et al: High incidence of SV40-like sequences detection in tumour and peripheral blood cells of Japanese osteosarcoma patients. Br J Cancer 2000; 82: 1677-1681